There was a small reduction in sdLDL-apoB with ERN/LRP treatment versus placebo (0.16 versus 0.18 g/L, P =0.23), but this did not reach statistical significance (Table 5 ).
← all excerpts
Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients.
1
—
—